Skip to main
VANI

VANI Stock Forecast & Price Target

VANI Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vivani Medical Inc. is positioned favorably due to the promising potential of its candidate NPM-139, which could enhance the safety and tolerability of existing therapies such as semaglutide, thereby reducing therapy discontinuation rates. The encouraging clinical data indicating that NPM-139 achieves approximately 20% weight loss sustained over six months further underscores its therapeutic potential and market opportunity. As a preclinical-stage biopharmaceutical company, the advancements in both its Biopharm and Neuromodulation divisions reflect a strong commitment to developing innovative treatments for chronic diseases, contributing to a bullish outlook on its stock.

Bears say

Vivani Medical Inc faces significant risks that contribute to a negative outlook on its stock, particularly surrounding the clinical viability and commercial potential of its lead product, NPM-139. The company's reliance on this product is underscored by multiple potential points of failure: lack of success in clinical trials, difficulties in obtaining regulatory approval, and challenges in capturing market share against competitive pressures. Additionally, the concern over dilution risk further exacerbates the potential for negative financial implications, creating uncertainty about the company's future capital structure and shareholder value.

VANI has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vivani Medical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vivani Medical Inc (VANI) Forecast

Analysts have given VANI a Strong Buy based on their latest research and market trends.

According to 1 analysts, VANI has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vivani Medical Inc (VANI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.